A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer

Cancer Research

Volumn 57, Issue 7, 1997, Pages 1329-1334

  Sim, B Kim Lee ^a   O'Reilly, Michael S ^b   Liang, Hong ^a   Fortier, Anne H ^a   He, Weixuan ^a   Madsen, John W ^a   Lapcevich, Randall ^a   Nacy, Carol A ^a  

^a ENTREMED INC   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOSTATIN; RECOMBINANT PROTEIN;

ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEWIS CARCINOMA; METASTASIS INHIBITION; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; TUMOR VASCULARIZATION;

ANGIOSTATINS; ANIMALS; ANTINEOPLASTIC AGENTS; CATTLE; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; IMMUNOHISTOCHEMISTRY; KRINGLES; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PLASMINOGEN; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED; VON WILLEBRAND FACTOR;

EID: 0030935029     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst., 82: 4-6, 1990.
2. Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., and Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature (Lond.), 362: 841-844, 1993.
3. Hori, A., Sasada, R., Matsutani, E., Naito, K., Sakura, Y., Fujita, T., and Kozai, Y. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res., 51: 6180-6184, 1991.
4. Millauer, B., Shawver, L. K., Plate, K. H., Risau, W., and Ullrich, A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature (Lond.), 367: 576-579, 1994.
5. Sugarbaker, E. V., Thornthwaite, J., and Ketcham, A. S. Inhibitory effect of a primary tumor on metastasis. In: S. B. Day, W. P. L. Myers, P. Stansly, S. Garattini, and M. G. Lewis (eds.), Progress in Cancer Research and Therapy, pp. 227-240. New York: Raven Press, 1977.
6. Gorelik, E. Concomitant tumor immunity and the resistance to a second tumor challenge. Adv. Cancer Res., 39: 71-120, 1983.
7. Prehn, R. T. The inhibition of tumor growth by tumor mass. Cancer Res., 51: 2-4, 1991.
8. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79: 315-328, 1994.
9. Degen, S. J. F., Bell, S. M., Schaefer, L. A., and Elliott, R. W. Characterization of the c-DNA coding for mouse plasminogen and localization of the gene to mouse chromosome 17. Genomics, 8: 49-61, 1990.
10. Sottrup-Jensen, L., Claeys, H., Zajdel, M., Petersen, T. E , and Magnusson, S. The primary structure of human plasminogen: isolation of two lysine-binding fragments and one ''mini"-plasminogen (MW, 38,000) by elastase-catalyzed-specific limited proteolysis. In: J. F. Davidson, R. M. Rowan, M. M. Samama, and P. C. Desnoyers (eds.), Progress in Chemical Fibrinolysis and Thrombolysis, pp. 191-209. New York: Raven Press, 1978.
11. O'Reilly, M. S., Holmgren, L., Chen, C., and Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med., 2: 689-692, 1996.
12. Forsgren, M., Raden, B. Israelsson, M., Larsson, K., and Heden, L. O. Molecular cloning and characterization of a full-length cDNA clone for human plasminogen. FEBS Lett., 213: 254-260, 1987.
13. Folkman, J., Haudenschild, C. C., and Zetter, B. R. Long-term culture of capillary endothelial cells. Proc. Natl. Acad. Sci. USA, 76: 5217-5221, 1979.
14. Wiman, B., and Wallen, P. The specific interaction between plasminogen and fibrin. A physiological role of the lysine binding site in plasminogen. Thromb. Res., 10: 213-222, 1977.
15. Lerch, P. G., Rickli, E. E., Lergier, W., and Gillessen, D. Localization of individual lysine-binding regions in human plasminogen and investigations on their complex forming properties. Eur. J. Biochem., 107: 7-13, 1980.
16. Whitefleet-Smith, J., Davidson, D. J., Fraser, M. J., and Castellino, F. J. Expression of human plasminogen cDNA in a baculovirus vector-infected insect cell system. Arch. Biochem. Biophys., 271: 390-399, 1989.
17. Hayes, M. L., and Castellino, F. J. Carbohydrate of the human plasminogen variants. I. Structure of the asparagine-linked oligosaccharide unit. J. Biol. Chem., 254: 8772-8776, 1979.
18. Hayes, M. L., and Castellino, F. J. Carbohydrate of the human plasminogen variants. II. Structure of the o-glycosidically linked oligosaccharide unit. J. Biol. Chem., 254: 8777-8780, 1979.
19. Tschopp, J. F., Sverlow, G., Kosson, R., Craig, W., and Grinna, L. High level secretion of glycosylated invertase in the methylotropic yeast Pichia pastoris. BioTechnology, 5: 1305-1308, 1987.
20. Guzzetta, A. W., Basa, L. J., Hancock, W. S., Keyt, B. A., and Bennett, W. F. Identification of carbohydrate structures in glycoprotein peptide maps by the use of LC/MS with selected ion extraction with special reference to tissue plasminogen activator and a glycosylation variant produced by site directed mutagenesis. Anal. Chem., 65: 2953-2962, 1993.
21. Sako, D., Chang, X., Barone, K. M., Vachino, G., White, H. M., Shaw, G., Veldman, G. M., Bean, K. M., Ahern, T. J., Furie, B., Cumming, D. A., and Larsen, G. R. Expression cloning of a functional glycoprotein ligand for P-selectin. Cell, 75: 1179-1186, 1993.
22. Sim, B. K. L., Chitnis, C. E., Wasniowska, K., Hadley, T. J., and Miller, L. H. Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum. Science (Washington DC), 264: 1941-1944, 1994.
23. Gonzalez-Gronow, M., Grenett, H. E., Fuller, G. M., and Pizzo, S. V. The role of carbohydrate in the function of human plasminogen: comparison of the protein obtained from molecular cloning and expression in Escherichia coli and COS cells. Biochim. Biophys. Acta, 1039: 269-276, 1990.
24. Ponting, C. P., Marshall, J. M., and Cederholm-Williams, S. A. Plasminogen: a structural review. Blood Coagul. & Fibrinolysis, 3: 605-614, 1992.
25. Fidler, I. J., and Ellis, L. M. The implications of angiogenesis for the biology and therapy of cancer metastases. Cell, 79: 185-188, 1994.
26. Xie, B., Dong, Z., and Fidler, I. J. Regulatory mechanisms for the expression of type IV collagenases/gelatinases in murine macrophages. J. Immunol., 152: 3637-3644, 1994.
27. Shih, G. C., and Hajjar, K. A. Plasminogen and plasminogen activator assembly on the human endothelial cell. Proc. Soc. Exp. Biol. Med., 202: 258-264, 1993.
28. Wu, H., Fang, R., Hau, J., Wu, D., Chang, B., Lin, T., and Shi, G. The binding of plasminogen fragments to cultured human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun., 188: 703-711, 1992.
29. Hajjar, K. A., Jacovina, A. T., and Chacko, J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. J. Biol. Chem., 269: 21191-21197, 1994.
30. Cesarman, G. M., Guevara, C. A., and Hajjar, K. A. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). J. Biol. Chem., 269: 21198-21203, 1994.
31. Hajjar, K. A., and Nachman, R. L. Endothelial cell-mediated conversion of Glu-plasminogen to Lys-plasminogen, Further evidence for assembly of the fibrinolytic system on the endothelial cell surface. J. Clin. Invest., 82: 1769-1778, 1988.